LUCENTIS is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD).
Randomized, double-masked, 2-year study of LUCENTIS 0.5 mg (n=240) vs sham (n=238) in patients with minimally classic or occult CNV lesions and BCVA ≤20/320.
PRIMARY OUTCOME: 1 YEAR
% losing <15 ETDRS letters.
Randomized, double-masked, 2-year study of LUCENTIS 0.5 mg (n=139) vs active control (vPDT, n=143) in patients with predominantly classic CNV lesions.
PRIMARY OUTCOME: 1 YEAR
% losing <15 ETDRS letters.
“Maintained” was defined as losing <15 ETDRS letters from baseline.
*Adjusted estimate based on the stratified model; P<0.01.1
Randomized, double-masked, active treatment–controlled, 2-year study of LUCENTIS 0.5 mg (N=550) monthly or less frequently in patients with wAMD.
PRIMARY OUTCOME – 1 YEAR: Mean change in BCVA from baseline at year 1 with a prespecified noninferiority comparison of LUCENTIS monthly and less-frequent dosing (margin of 4 letters).5
THE PRIMARY END POINT WAS NOT MET. AT YEAR 1, THE LESS-FREQUENT DOSING ARM DID NOT MEET THE NONINFERIORITY COMPARISON.5
In HARBOR, patients received 3 initial monthly doses followed by PRN dosing with regular monthly assessment through 2 years. Monthly dosing is more effective. Patients should be regularly assessed to evaluate treatment need.
9.9 weeks=average treatment interval†
†This analysis calculated the average interval between injections for study participants after 3 initial monthly doses, and included only patients in the less-frequent dosing arm who completed 24 months of the study (n=232).6
Compared to the less-frequent dosing arm, patients in the monthly treatment arm gained 1 to 2 additional letters on average. After 3 initial monthly doses, patients in the less-frequent dosing arm maintained clinically meaningful VA gains through year 1 and year 2.1,6
‡Among patients who completed the 2-year study.
Limitations of this analysis include that it is post hoc (ie, not prespecified). The statistical significance of these results cannot be determined, and the clinical significance of these results is unknown.
MEAN CHANGE IN BCVA FROM BASELINE AT 2 YEARS |
---|
+8.4 | with PED (n=598) |
---|---|
+7.9 | without PED (n=499) |
A post hoc analysis of HARBOR examined the effect of a baseline PED on visual outcomes
PED, pigment epithelial detachment; PRN, pro re nata; VA, visual acuity; VEGF, vascular endothelial growth factor.
VIEW 1 & 2 were two randomized, double-masked, 96-week, active treatment–controlled studies of LUCENTIS 0.5 mg monthly vs aflibercept 2.0 mg monthly or every 8 weeks, or aflibercept 0.5 mg monthly in patients with wAMD (N=2457).
PRIMARY OUTCOME: MAINTENANCE§ OF VISION AT 52 WEEKS
Noninferiority of aflibercept arms to LUCENTIS (margin of 10%) in the proportion of eyes maintaining vision.
§“Maintained” was defined as losing <15 ETDRS letters from baseline.
PRIMARY OUTCOMES8,9
LUCENTIS 0.5 mg was the active control in the VIEW 1 and 2 trials. Prespecified primary and secondary end points were assessed at week 52.8,9
||Percentages reflect a combination of aflibercept 2Q4 (2.0 mg every 4 weeks) and 2Q8 (2.0 mg every 8 weeks) treatment groups. Last observation carried forward: full analysis set.8.9
VIEW 1 & 2 were two randomized, double-masked, 96-week, active treatment–controlled studies of LUCENTIS 0.5 mg monthly vs aflibercept 2.0 mg monthly or every 8 weeks, or aflibercept 0.5 mg monthly in patients with wAMD (N=2457).
PRIMARY OUTCOME: MAINTENANCE¶ OF VISION AT 52 WEEKS
Comparison of aflibercept arms to LUCENTIS (margin of 10%) in the proportion of eyes maintaining vision.
¶“Maintained” was defined as losing <15 ETDRS letters from baseline.
VIEW 1 AND 2 DOSING SCHEDULE8,9 |
---|
0-52 WEEKS | 52-96 WEEKS |
---|---|
LUCENTIS 0.5 mg monthly (n=609) | Dosed at Least Every 12 Weeks, Additional Doses as Needed. |
Aflibercept 2.0 mg every 8 weeks (n=616) | |
Aflibercept 2.0 mg monthly (n=617) | |
Aflibercept 0.5 mg monthly (n=615) | |
Patients continued on their initially randomized dosing through 96 weeks. |
VIEW 1 AND 2 DOSING SCHEDULE8,9 |
---|
0-52 WEEKS | ||
---|---|---|
LUCENTIS 0.5 mg monthly (n=609) | ||
Aflibercept 2.0 mg every 8 weeks (n=616) | ||
Aflibercept 2.0 mg monthly (n=617) | ||
Aflibercept 0.5 mg monthly (n=615) | ||
52-96 WEEKS | ||
Dosed at Least Every 12 Weeks, Additional Doses as Needed. |
||
Patients continued on their initially randomized dosing through 96 weeks. |
#A total of 2412 patients were treated and evaluated for efficacy in VIEW 1 and VIEW 2 studies.9
IN YEAR 2 |
---|
4.7 | Average Injections With LUCENTIS in the VIEW 1 and 2 Pooled Analysis10 |
---|
ADVERSE REACTIONS | LUCENTIS 0.5 mg MONTHLY (n=379), % | CONTROL (n=379), % |
---|
Conjunctival Hemorrhage | 74% | 60% | |||
Eye Pain | 35% | 30% | |||
Vitreous Floaters | 27% | 8% | |||
Increased Intraocular Pressure | 24% | 7% | |||
Vitreous Detachment | 21% | 19% | |||
Intraocular Inflammation | 18% | 8% |
LUCENTIS 0.5 mg MONTHLY (n=379), % | CONTROL (n=379), % |
---|---|
ADVERSE REACTIONS |
Conjunctival Hemorrhage | |
74% | 60% |
Eye Pain | |
35% | 30% |
Vitreous Floaters | |
27% | 8% |
Increased Intraocular Pressure | |
24% | 7% |
Vitreous Detachment | |
21% | 19% |
Intraocular Inflammation | |
18% | 8% |
ADVERSE REACTIONS | LUCENTIS 0.5 mg MONTHLY (n=379), % | CONTROL (n=379), % |
---|
Nasopharyngitis | 16% | 13% | |||
Headache | 12% | 9% | |||
Arthralgia | 11% | 9% | |||
Bronchitis | 11% | 9% |
LUCENTIS 0.5 mg MONTHLY (n=379), % | CONTROL (n=379), % |
---|---|
ADVERSE REACTIONS |
Nasopharyngitis | |
16% | 13% |
Headache | |
12% | 9% |
Arthralgia | |
11% | 9% |
Bronchitis | |
11% | 9% |
SERIOUS ADVERSE REACTIONS RELATED TO THE INJECTION PROCEDURE IN <0.1% OF INTRAVITREAL INJECTIONS1 |
---|
Endophthalmitis | Rhegmatogenous Detachment | Iatrogenic Traumatic Cataract |
SERIOUS ADVERSE REACTIONS RELATED TO THE INJECTION PROCEDURE IN <0.1% OF INTRAVITREAL INJECTIONS1 |
---|
Endophthalmitis | |
Rhegmatogenous Detachment | |
Iatrogenic Traumatic Cataract |
SERIOUS ADVERSE EVENTS | LUCENTIS 0.5 mg MONTHLY (n=239), % (n) | SHAM (n=236), % (n) |
---|
APTC ATEs|||| | 4.6% (11) | 3.8% (9) |
---|---|---|
Nonfatal Myocardial Infarction (MI) | 1.3% (3) | 1.7% (4) |
Nonfatal Stroke | 2.5% (6) | 0.8% (2) |
Vascular Death | 1.3% (3) | 1.7% (4) |
Death of Unknown Cause | 1.3% (3) | 0.8% (2) |
LUCENTIS 0.5 mg MONTHLY (n=239), % (n) | SHAM (n=236), % (n) |
---|---|
SERIOUS ADVERSE EVENTS |
APTC ATEs|||| | |
4.6% (11) | 3.8% (9) |
Nonfatal Myocardial Infarction (MI) | |
1.3% (3) | 1.7% (4) |
Nonfatal Stroke | |
2.5% (6) | 0.8% (2) |
Vascular Death | |
1.3% (3) | 1.7% (4) |
Death of Unknown Cause | |
1.3% (3) | 0.8% (2) |
SERIOUS ADVERSE EVENTS | LUCENTIS 0.5 mg MONTHLY (n=140), % (n) | VERTEPORFIN PDT (n=143), % (n) |
---|
APTC ATEs|||| | 5.0% (7) | 4.2% (6) |
---|---|---|
Nonfatal Myocardial Infarction (MI) | 3.6% (5) | 1.4% (2) |
Nonfatal Stroke | 0 | 1.4% (2) |
Vascular Death | 1.4% (2) | 2.1% (3) |
Death of Unknown Cause | 0.7% (1) | 1.4% (2) |
LUCENTIS 0.5 mg MONTHLY (n=140), % (n) | VERTEPORFIN PDT (n=143), % (n) |
---|---|
SERIOUS ADVERSE EVENTS |
APTC ATEs|||| | |
5.0% (7) | 4.2% (6) |
Nonfatal Myocardial Infarction (MI) | |
3.6% (5) | 1.4% (2) |
Nonfatal Stroke | |
0 | 1.4% (2) |
Vascular Death | |
1.4% (2) | 2.1% (3) |
Death of Unknown Cause | |
0.7% (1) | 1.4% (2) |
SERIOUS ADVERSE EVENTS | LUCENTIS 0.5 mg MONTHLY (n=274), % (n) | LUCENTIS 0.5 mg LESS FREQUENT (n=275), % (n) |
---|
APTC ATEs|||| | 6.6% (18) | 4.7% (13) |
---|---|---|
Nonfatal Myocardial Infarction (MI) | 2.6% (7) | 1.8% (5) |
Nonfatal Stroke | 0.7% (2) | 0.4% (1) |
Vascular Death | 3.3% (9) | 2.5% (7) |
Death of Unknown Cause | 0.7% (2) | 0.4% (1) |
LUCENTIS 0.5 mg MONTHLY (n=274), % (n) | LUCENTIS 0.5 mg LESS FREQUENT (n=275), % (n) |
---|---|
SERIOUS ADVERSE EVENTS |
APTC ATEs|||| | |
6.6% (18) | 4.7% (13) |
Nonfatal Myocardial Infarction (MI) | |
2.6% (7) | 1.8% (5) |
Nonfatal Stroke | |
0.7% (2) | 0.4% (1) |
Vascular Death | |
3.3% (9) | 2.5% (7) |
Death of Unknown Cause | |
0.7% (2) | 0.4% (1) |
LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
Rosenfeld PJ, et al; MARINA Study Group. N Engl J Med. 2006;355:1419-1431.
Rosenfeld PJ, et al; MARINA Study Group. N Engl J Med. 2006;355:1419-1431.
Brown DM, et al; ANCHOR Study Group. Ophthalmology. 2009;116:57-65.
Brown DM, et al; ANCHOR Study Group. Ophthalmology. 2009;116:57-65.
Data on file. South San Francisco, CA: Genentech, Inc.
Data on file. South San Francisco, CA: Genentech, Inc.
Busbee BG, et al; HARBOR Study Group. Ophthalmology. 2013;120:1046-1056.
Busbee BG, et al; HARBOR Study Group. Ophthalmology. 2013;120:1046-1056.
Ho AC, et al; HARBOR Study Group. Ophthalmology. 2014;121:2181-2192.
Ho AC, et al; HARBOR Study Group. Ophthalmology. 2014;121:2181-2192.
Sarraf D, et al. Ophthalmology. 2016;123(10):2213-2224.
Sarraf D, et al. Ophthalmology. 2016;123(10):2213-2224.
Heier JS, et al; VIEW 1 and VIEW 2 Study Groups. Ophthalmology. 2012;119(12):2537-2548.
Heier JS, et al; VIEW 1 and VIEW 2 Study Groups. Ophthalmology. 2012;119(12):2537-2548.
Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.
Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.
Schmidt-Erfurth U, et al. Ophthalmology. 2014;121:193-201.
Schmidt-Erfurth U, et al. Ophthalmology. 2014;121:193-201.
The Product and Administration Co-pay Programs (“Programs”) are valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD), TRICARE or any other federal or state government program (collectively, “Government Programs”) to pay for their Genentech medicine and/or administration services are not eligible. The Programs are not valid if the costs are eligible to be reimbursed in their entirety by private insurance plans or other programs.
Under the Programs, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine or administration of the Genentech medicine (see Program specific details available at the Program Website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Programs assist with the cost of the Genentech medicine and the Genentech medicine administration only. It does not assist with the cost of other administrations, medicines, procedures or office visit fees. After reaching the maximum Programs’ benefit amounts, the patient will be responsible for all remaining out-of-pocket expenses. The Programs’ benefit amounts cannot exceed the patient’s out-of-pocket expenses for the Genentech medicine or administration fees of the Genentech medicine. The maximum Programs’ benefits will reset every January 1st. The Programs are not health insurance or a benefit plan. The patient’s non-governmental insurance is the primary payer. The Programs do not obligate use of any specific medicine or provider. The Drug Co-pay Program is not available or valid for patients receiving free medicine from the Genentech Patient Foundation. The Administration Co-pay Program is valid for patients receiving free medicine from the Genentech Patient Foundation. The Product and Administration Programs are not valid for patients receiving assistance from any other charitable organization for the same expenses covered by the Programs. The Programs’ benefits cannot be combined with any other rebate, free trial or other offer for the Genentech medicine or administration of the Genentech medicine. No party may seek reimbursement for all or any part of the benefits received through these Programs.
The Programs may be accepted by participating pharmacies, physicians’ offices or hospitals. Once a patient is enrolled, the Programs will honor claims with a date of service that precedes the Programs’ enrollment by 180 days. Claims must be submitted within 365 days from the date of service unless otherwise indicated. Use of these Programs must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physicians’ offices and hospitals are responsible for reporting the receipt of all the Programs’ benefits as required by any insurer or by law. Programs’ benefits may not be sold, purchased, traded or offered for sale.
The patient or their guardian must be 18 years of age or older to receive assistance from the Programs. The Programs are only valid in the United States and U.S. Territories and are void where prohibited by law. The Drug Co-pay Program shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The Administration Co-pay Program is not valid for Massachusetts or Rhode Island residents. Eligible patients will be automatically re-enrolled in the Programs on an annual basis. Eligible patients will be removed from the Programs after 3 years of inactivity (e.g., no claims submitted in a 3-year timeframe). Programs eligibility and automatic re-enrollment are contingent upon the patient’s ability to meet all the requirements set forth by the Programs. Healthcare providers may not advertise or otherwise use the Programs as a means of promoting their services or Genentech medicines to patients.
The value of the Programs is intended exclusively for the benefit of the patient. The funds made available through the Programs may only be used to reduce the out-of-pocket costs for the patient enrolled in the Programs. The Programs are not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented programs that adjust patient cost-sharing obligations based on the availability of support under the Programs and/or excludes the assistance provided under the Programs from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Programs. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply from Genentech programs. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.